Icono del sitio DR HEALTH JOURNAL

Myocardial localization of coronavirus in COVID‐19 cardiogenic shock

Redacción

Authors:Guido Tavazzi, Carlo Pellegrini, Marco Maurelli, Mirko Belliato, Fabio Sciutti, Andrea Bottazzi, Paola Alessandra Sepe, Tullia Resasco,  Rita Camporotondo, Raffaele Bruno, Fausto Baldanti, Stefania Paolucci, Stefano Pelenghi, Giorgio Antonio Iotti, Francesco Mojoli, Eloisa Arbustini

Source: https://onlinelibrary.wiley.com

Introduction

Acute myocardial involvement in coronavirus disease 2019 (COVID‐19) is currently described as ‘acute cardiac injury’, defined as blood levels of cardiac biomarkers [high‐sensitivity troponin I (hs‐TnI)] above the 99th‐percentile upper reference limit. It is described in more than 20% of patients and seems to be related to increased mortality.1, 2 The pathogenesis of acute myocardial injury is unknown. The diagnosis is based upon clinical data, imaging and biomarkers of acute cardiac damage3, 4; the identification of the cause, either myocardial inflammation (myocarditis or myopericarditis5), or necrosis, is clinically relevant for the correct diagnostic and therapeutic management of patients, especially those with severe infections admitted to the intensive care unit (ICU).

We describe a COVID‐19 patient with flu‐like symptoms rapidly degenerating into respiratory distress, hypotension, and cardiogenic shock. He was successfully treated with mechanical ventilation and venous‐arterial extracorporeal membrane oxygenation (VA‐ECMO) implantation as a bridge to recovery. Endomyocardial biopsy (EMB) showed low‐grade myocardial inflammation and coronavirus particles. Twelve days after weaning from ECMO, with complete normalization of cardiac function, the patient died of Gram‐negative septic shock. This first case unquestionably shows that the heart can be directly involved in the infection with clinical manifestations similar to those of fulminant myocarditis but with pathology evidence of very low‐grade myocardial inflammation.

Case description

Acute clinical manifestation and evolution

A 69‐year‐old patient presented to the emergency department of the main hospital of a ‘red zone’ town in Lombardy, Italy. He had been complaining of worsening dyspnoea, persistent cough, and weakness since 4 days. A lung computed tomography scan showed diffuse bilateral interstitial inflammation with sub‐pleural consolidations. The nasopharyngeal swab tested positive for COVID‐19 on real‐time reverse transcriptase‐polymerase chain reaction assay. Blood analysis demonstrated high inflammatory markers and lymphopenia (white blood cell count 23080/mm3, neutrophils 91.4%, lymphocytes 1.4%, C‐reactive protein 52.7 mg/L) and increased hs‐TnI (4332 ng/L). Arterial blood gas analysis showed severe metabolic acidosis with hyperlactacidaemia (pH 7.2, excess basis –6 mEq/L, lactates 9 mmol/dL) and hypoxaemia. Non‐invasive ventilation was initiated. The first echocardiography showed a dilated left ventricle [left ventricular (LV) end‐diastolic diameter 56 mm], severe and diffuse LV hypokinesia (LV ejection fraction 34%). Three hours later, LV ejection fraction dropped to 25% and estimated cardiac index was 1.4 L/min/m2. Coronary angiography findings were unremarkable. An intra‐aortic balloon pump (IABP) was placed on top of adrenaline (0.07 μg/kg/min), and noradrenaline (0.1 μg/kg/min) was added for worsening hypotension (systolic blood pressure: 80/67/60 mmHg). The mobile team from our third level ECMO center was activated for on‐site implantation of VA‐ECMO and patient retrieval to our hospital. After ECMO institution, the patient developed sudden and marked desaturation requiring orotracheal intubation. On admission to our ICU, due to maintenance of minimal ventricular ejection and aortic valve opening, the inotropic support was gradually decreased and eventually stopped to prevent adrenergic stimulation to the myocardium (online supplementary Appendix S1). EMB was performed and a venous cannula was added at the right jugular vein site for persistent severe hypoxaemia, thus upgrading the VA‐ECMO to venous‐arterial‐venous ECMO. LV function progressively recovered up to normal levels on day 5, when both ECMO and IABP were discontinued. Twelve days after weaning from ECMO, the patient suddenly developed Gram‐negative pneumonia (Pseudomonas aeruginosa and Klebsiella pneumoniae) and died of septic shock within a few hours, without any further LV function impairment.

Endomyocardial biopsy

Endomyocardial biopsy was performed as per protocol in non‐ischaemic cardiogenic shock. Myocardial samples were rapidly processed for light (n = 3) and electron microscopy (n = 1). The pathologic study showed low‐grade interstitial and endocardial inflammation (Figure 1A and 1B). Large (>20 μm), vacuolated, CD68‐positive macrophages were seen with immune‐light microscopy (Figure 1C and 1D); they were ultrastructurally characterized by cytopathy, with membrane damage and cytoplasmic vacuoles (Figure 1E). The ultrastructural study demonstrated single or small groups of viral particles with the morphology (dense round viral envelope and electron‐dense spike‐like structures on their surface) and size (variable between 70 and 120 nm) of coronaviruses (Figure 2). COVID‐19 infected Vero cells were used as control. The viral particles were observed in cytopathic, structurally damaged interstitial cells that demonstrated loss of the cytoplasmic membrane integrity (Figure 3).

Figure 1

Open in figure viewerPowerPoint
Light microscopy immunostaining of the inflammatory infiltrate. (A,B) Low‐ and high‐power views of endomyocardial biopsy, with sparse CD45RO positive interstitial cells. (C,D) Large, vacuolated macrophages immunostained with anti‐CD68 antibodies. (E) Ultrastructural morphology of a large and cytopathic macrophage. (A–D: the bar scale is in the left low corner of each panel. E: the bar scale is in the right low corner of the panel and corresponds to 2 μm).

Figure 2

Open in figure viewerPowerPoint
Examples of small groups of viral particles (A and B; panel C shows a higher magnification of one of the viral particles squared in dashed red box of panel B) or single particles (D–F) observed within the interstitial cells of the myocardium of the patient. The red arrows indicate the most typical and easy‐to‐recognize viral particles, whose size varies from about 70 nm to 120 nm (see the white bars in the panels). Morphology also shows small differences with more or less prominent spikes of the viral crown. The morphology may also show viral particle disruption (E, green arrow) or attenuation of spikes of the crown (D and F), or viral particles in budding attitude (F). (Bar scale: A and B, 200 nm; C, 50 nm; D, 100 nm; E, 100 nm; F, 50 nm).

Figure 3

Open in figure viewerPowerPoint
Electron micrograph showing a cytopathic interstitial inflammatory cell (A) that contains viral particles (some of them are magnified in panel B that corresponds to the yellow squared area of panel A). The interstitial cell is in close contact with the adjacent cardiac myocyte (left). The viral particles show diameter variability in the range of 70–120 nm. Although the inflammatory cell and myocyte are closely adjacent, no viral particles are observed in the myocyte.

Cardiac myocytes showed non‐specific features consisting of focal myofibrillar lysis, and lipid droplets. We did not observe viral particles in myocytes and endothelia. Small intramural vessels were free from vasculitis and thrombosis. EMB did not show significant myocyte hypertrophy or nuclear changes; interstitial fibrosis was minimal, focal, and mainly perivascular.

Discussion

We describe the first case of biopsy‐proven myocardial localization of viral particles with morphology and size typical of coronavirus in a COVID‐19 patient presenting with cardiogenic shock. While the clinical presentation was suggestive for severe and necrotizing acute myocarditis, the pathologic study demonstrated low‐grade myocardial inflammation and absence of myocyte necrosis. Pathologic studies are especially needed for the characterization of acute myocardial injury in COVID‐19 patients admitted to the ICU. Our ultrastructural findings are similar to those observed in autopsy samples from a patient with T‐cell lymphoma and Middle East respiratory syndrome coronavirus (MERS‐CoV),6 where viral particles were found in the cytoplasm of pneumocytes and alveolar macrophages, renal proximal tubular epithelial cells, and macrophages infiltrating the skeletal muscle. Our observation of myocardial localization implies either a viraemic phase or, alternatively, the migration of infected alveolar macrophages in extra‐pulmonary tissues. Although the main target cells for the virus to infect are epithelial cells and macrophages of the respiratory tract,7 COVID‐19 RNA has been detected in the small and large intestine, lymph nodes, spleen, liver, heart, kidney, skeletal muscle, adrenal gland, and cerebrum, suggesting extra‐pulmonary dissemination and virus localization in different types of tissues and fluids.8 We observed viral particles in interstitial cytopathic macrophages and their surroundings. Vice versa, we did not observe viral particles in cardiac myocytes and, therefore, we cannot infer on viral cardiotropism. Cardiac myocytes showed non‐specific damage that was mainly characterized by focal myofibrillar lysis. In addition, we did not observe cytopathic endothelia and small intramural vessel inflammation or thrombosis. Other cases are needed to confirm this observation.

Cardiogenic shock clinically mimicked fulminant myocarditis and was treated according to standard protocols,9, 10 including implantation of VA‐ECMO11 that prevents an excessive and detrimental catecholaminergic stimulation to the myocardium. VA‐ECMO as a bridge to recovery should be considered for COVID‐19 patients with severe acute myocardial injury.12, 13 Since different mechanisms (oxygen supply/demand imbalance with or without coronary artery disease, increased right ventricular afterload due to respiratory acidosis, hypoxaemia and positive pressure ventilation) can cause acute myocardial injury,14 the precise identification of the cause is essential to target the treatment accordingly. The extent of local tissue damage and the cytokine storm triggered by the host immune response may both contribute to the severity of the disease. On the basis of the theoretical hyper‐inflammatory response and on a re‐analysis of data from a controlled trial on interleukin‐1 blockade in sepsis, showing significant survival benefit in patients with hyper‐inflammation,15 randomized controlled trials on specific anti‐inflammatory treatments are advocated.

This unique case demonstrates that COVID‐19 can localize in organs/tissues other than the lung. Either transient viraemia or infected macrophage migration from the lung likely occurs in COVID‐19 patients with non‐ischaemic acute myocardial injury. Identification of the cause of acute myocardial injury may contribute to explain the different evolution of the severe SARS‐CoV‐2 infection and to plan treatments according to the type of myocardial injury.

Acknowledgments

The authors are grateful to Monica Concardi for the excellent technical support for the electron microscopy study, to Elena Percivalle for the COVID‐19 infected Vero cells obtained from routine diagnostic samples and to Antonella Degani, CCP for her invaluable help in managing the extracorporeal cardiocirculatory support. In addition, the authors thank all the nurses and physicians involved in the management of such epidemics at IRCCS Policlinico San Matteo Foundation and the Pavia COVID‐19 Task Force.

Funding

Research and studies on myocardial diseases and endomyocardial biopsy are supported by funds of ‘Ricerca Corrente’, granted by the Ministry of Health to the IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Conflict of interest: G.T. received fees for lectures by GE Healthcare, outside the present work. F.M. received fees for lectures from GE Healthcare, Hamilton Medical, SEDA SpA, outside the present work. The other authors have nothing to disclose.

References

  • 1Huang C, Wang Y, Li X, Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497– 506.
  • 2 Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan. China. JAMA 2020 Feb 7. https://doi.org/10.1001/jama.2020.1585 [Epub ahead of print].
  • 3 Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID‐19 in China. Clin Res Cardiol 2020 Mar 11. https://doi.org/10.1007/s00392‐020‐01626‐9 [Epub ahead of print].
  • 4 Madjid M, Safavi‐Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020 Mar 27. https://doi.org/10.1001/jamacardio.2020.1286 [Epub ahead of print].
  • 5 Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M. Cardiac involvement in a patient with coronavirus disease 2019 (COVID‐19). JAMA Cardiol 2020 Mar 27. https://doi.org/10.1001/jamacardio.2020.1096 [Epub ahead of print].
  • 6Alsaad KO, Hajeer AH, Al Balwi M, Al Moaiqel M, Al Oudah N, Al Ajlan A, AlJohani S, Alsolamy S, Gmati GE, Balkhy H, Al‐Jahdali HH, Baharoon SA, Arabi YM. Histopathology of Middle East respiratory syndrome coronovirus (MERS‐CoV) infection – clinicopathological and ultrastructural study. Histopathology 2018; 72: 516– 524.
  • 7Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY; SARS Study Group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319– 1325.
  • 8 Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS‐CoV‐2 in different types of clinical specimens. JAMA 2020 Mar 11. https://doi.org/10.1001/jama.2020.3786 [Epub ahead of print].
  • 9Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation 2020; 141: e69– e92.
  • 10van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017; 136: e232– e268.
  • 11 Lorusso R, Centofanti P, Gelsomino S, Barili F, Di Mauro M, Orlando P, Botta L, Milazzo F, Actis Dato G, Casabona R, Casali G, Musumeci F, De Bonis M, Zangrillo A, Alfieri O, Pellegrini C, Mazzola S, Coletti G, Vizzardi E, Bianco R, Gerosa G, Massetti M, Caldaroni F, Pilato E, Pacini D, Di Bartolomeo R, Marinelli G, Sponga S, Livi U, Mauro R, Mariscalco G, Beghi C, Miceli A, Glauber M, Pappalardo F, Russo CF; GIROC Investigators. Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a 5‐year multi‐institutional experience. Ann Thorac Surg 2016; 101: 919– 926.
  • 12 MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID‐19: the potential role of extracorporeal membrane oxygenation. JAMA 2020 Feb 19. https://doi.org/10.1001/jama.2020.2342 [Epub ahead of print].
  • 13 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid‐19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Feb 28. doi: 10.1056/NEJMoa2002032 [Epub ahead of print].
  • 14 Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, Jain SS, Burkhoff D, Kumaraiah D, Rabbani L, Schwartz A, Uriel N. Coronavirus disease 2019 (COVID‐19) and cardiovascular disease. Circulation 2020 Mar 21. https://doi.org/10.1161/CIRCULATIONAHA.120.046941 [Epub ahead of print].
  • 15Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM. Interleukin‐1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016; 44: 275– 281.

 

Salir de la versión móvil
Ir a la barra de herramientas